Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR3 | P32745 | 1/20 | 0.54 |
| ▸ | CALCRL | Q16602 | 1/20 | 0.52 |
| ▸ | MMP3 | P08254 | 4/20 | 0.47 |
| ▸ | MMP1 | P03956 | 3/20 | 0.47 |
| ▸ | PLG | P00747 | 1/20 | 0.45 |
| ▸ | LTA4H | P09960 | 1/20 | 0.44 |
| ▸ | TLR2 | O60603 | 1/20 | 0.44 |
| ▸ | MMP9 | P14780 | 2/20 | 0.43 |
| ▸ | GNPAT | O15228 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | MMP2 | P08253 | 1/20 | 0.43 |
| ▸ | KDM1A | O60341 | 1/20 | 0.43 |
| ▸ | Q9HBH1 | 1/20 | 0.43 | |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13684815 | 0.90 | SSTR3 (0.56) | SSTR3CALCRLMMP3MMP1PLG | |
| SCHEMBL24122417 | 0.87 | SMN1; SMN2 (0.46) | SSTR3GNPATSMN1; SMN2KDM1A | |
| SCHEMBL20420459 | 0.87 | CALCRL (0.56) | SSTR3CALCRLMMP3MMP1PLG | |
| SCHEMBL14872058 | 0.86 | SSTR3 (0.55) | SSTR3CALCRLMMP3LTA4HKDM1A | |
| SCHEMBL18494988 | 0.86 | SSTR3 (0.55) | SSTR3CALCRLMMP3LTA4HKDM1A | |
| SCHEMBL14821040 | 0.86 | SSTR3 (0.55) | SSTR3CALCRLMMP3LTA4HKDM1A | |
| SCHEMBL17706674 | 0.86 | SSTR3 (0.55) | SSTR3CALCRLMMP3LTA4HKDM1A | |
| SCHEMBL14821599 | 0.86 | MMP1 (0.57) | MMP3MMP1MMP9GNPATMMP2 | |
| SCHEMBL12245289 | 0.85 | SSTR3 (0.53) | SSTR3CALCRLMMP3MMP1PLG | |
| SCHEMBL22096459 | 0.85 | SSTR3 (0.51) | SSTR3CALCRLMMP3MMP1LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024094688-A1 | ANTI-GUCY2C ANTIBODY AND USES THEREOF | HEIDELBERG PHARMA RESEARCH GMBH (DE) | 2024-05-10 | — | — | WO | disclosed |
| US-20230355792-A1 | METHODS OF IMPROVING THE THERAPEUTIC INDEX | HEIDELBERG PHARMA RESEARCH GMBH (DE) | 2023-11-09 | — | — | US | disclosed |
| US-20230355792-A1 | METHODS OF IMPROVING THE THERAPEUTIC INDEX | HEIDELBERG PHARMA RESEARCH GMBH (DE) | 2023-11-09 | — | — | US | disclosed |
| WO-2023194539-A1 | METHODS OF IMPROVING THE THERAPEUTIC INDEX OF AMATOXIN-ANTIBODY CONJUGATES | HEIDELBERG PHARMA RESEARCH GMBH (DE) | 2023-10-12 | — | — | WO | disclosed |
| US-20230220001-A1 | METHOD FOR SYNTHESIS OF THIOETHER-CONTAINING PEPTIDES | HEIDELBERG PHARMA RESEARCH GMBH (DE) | 2023-07-13 | — | — | US | disclosed |
| WO-2022194988-A2 | B-LYMPHOCYTE SPECIFIC AMATOXIN ANTIBODY CONJUGATES | HEIDELBERG PHARMA RESEARCH GMBH (DE) | 2022-09-22 | — | — | WO | disclosed |
| WO-2022096604-A1 | COMPOSITION COMPRISING A COMBINATION OF IMMUNE CHECKPOINT INHIBITOR AND ANTIBODY-AMATOXIN CONJUGATE FOR USE IN CANCER THERAPY | HEIDELBERG PHARMA RESEARCH GMBH (DE) | 2022-05-12 | — | — | WO | disclosed |
| WO-2021255217-A1 | AMATOXIN AND AMATOXIN CONJUGATES FOR USE IN INHIBITION OF RNA VIRUS REPLICATION | HEIDELBERG PHARMA RESEARCH GMBH (DE) | 2021-12-23 | — | — | WO | disclosed |
| WO-2021250059-A1 | METHOD FOR SYNTHESIS OF THIOETHER-CONTAINING PEPTIDES | HEIDELBERG PHARMA RESEARCH GMBH (DE) | 2021-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230355792-A1 | METHODS OF IMPROVING THE THERAPEUTIC INDEX | CD47, ANXA5, MTX1 | SSTR3 958/4885CALCRL 1115/4885MMP3 1366/4885 |
| US-20230220001-A1 | METHOD FOR SYNTHESIS OF THIOETHER-CONTAINING PEPTIDES | TST, PTMS, CTH | SSTR3 9/4885CALCRL 1044/4885MMP3 3131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.